Department of Surgery and Science, University of Toyama, Toyama 930‑0194, Japan.
Department of Surgical Pathology, University of Toyama, Toyama 930‑0194, Japan.
Oncol Rep. 2014 Feb;31(2):613-8. doi: 10.3892/or.2013.2900. Epub 2013 Dec 5.
S-1 has been recommended as adjuvant chemotherapy in patients after curative surgery for gastric cancer. However, some patients suffer recurrence even after S-1 adjuvant chemotherapy. The present study was conducted to find a predictive marker of the efficacy of S-1 adjuvant chemotherapy. We examined the microRNA (miRNA) expression of 35 patients who underwent S-1 adjuvant chemotherapy after curative surgery (R0) for pathological stage II or III gastric cancer. miRNAs were extracted from formalin-fixed, paraffin-embedded specimens for analysis and miRNA expression was examined using miRNA oligo chips. Fifteen patients relapsed and 20 did not over 5 years. Five miRNAs (miR-92b, 422a, 4732-5p, 4758-3p and 221) were highly expressed according to the tumor/normal (T/N) ratio in the patients who relapsed but not in those who did not relapse (P-value <0.05) by microarray analysis. If tumors showed high expression of 4 miRNAs (miR-92b, 422a, 4732-5p and 4758-3p) their positive predictive value of relapse was 93.8% and negative predictive value was 92.3%. In this case, their disease-free survival rate and overall survival rate were very poor. Our findings indicate that miR-92b, miR‑422a, miR-4732-5p and miR-4758-3p are closely associated with relapse following S-1 adjuvant chemotherapy in gastric cancer.
S-1 已被推荐作为胃癌根治术后患者的辅助化疗药物。然而，一些患者在接受 S-1 辅助化疗后仍会复发。本研究旨在寻找 S-1 辅助化疗疗效的预测标志物。我们检测了 35 例接受根治性手术后（R0）病理分期 II 或 III 期胃癌 S-1 辅助化疗的患者的 microRNA（miRNA）表达。从福尔马林固定、石蜡包埋标本中提取 miRNA 进行分析，并使用 miRNA 寡核苷酸芯片检测 miRNA 表达。15 例患者在 5 年内复发，20 例未复发。根据肿瘤/正常（T/N）比值，微阵列分析显示，在复发患者中，有 5 个 miRNA（miR-92b、422a、4732-5p、4758-3p 和 221）表达较高，而在未复发患者中则无（P 值<0.05）。如果肿瘤显示 4 个 miRNA（miR-92b、422a、4732-5p 和 4758-3p）高表达，其复发的阳性预测值为 93.8%，阴性预测值为 92.3%。在这种情况下，他们的无病生存率和总生存率非常差。我们的研究结果表明，miR-92b、miR-422a、miR-4732-5p 和 miR-4758-3p 与胃癌 S-1 辅助化疗后复发密切相关。
